GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pieris Pharmaceuticals Inc (NAS:PIRS) » Definitions » Piotroski F-Score

Pieris Pharmaceuticals (Pieris Pharmaceuticals) Piotroski F-Score : 3 (As of May. 15, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Pieris Pharmaceuticals Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pieris Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Pieris Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

PIRS' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 5
Current: 3

During the past 11 years, the highest Piotroski F-Score of Pieris Pharmaceuticals was 5. The lowest was 1. And the median was 3.


Pieris Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Pieris Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pieris Pharmaceuticals Piotroski F-Score Chart

Pieris Pharmaceuticals Annual Data
Trend Jun14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 - 3.00 1.00 3.00

Pieris Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 1.00 2.00 2.00 3.00

Competitive Comparison of Pieris Pharmaceuticals's Piotroski F-Score

For the Biotechnology subindustry, Pieris Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pieris Pharmaceuticals's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pieris Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Pieris Pharmaceuticals's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -13.183 + 3.976 + -10.752 + -4.584 = $-24.54 Mil.
Cash Flow from Operations was -10.996 + -13.431 + -9.723 + -19.669 = $-53.82 Mil.
Revenue was 1.936 + 20.055 + 19.52 + 1.299 = $42.81 Mil.
Gross Profit was 1.936 + 20.055 + 19.52 + 1.299 = $42.81 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(95.49 + 82.258 + 87.544 + 59.376 + 38.68) / 5 = $72.6696 Mil.
Total Assets at the begining of this year (Dec22) was $95.49 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $38.68 Mil.
Total Current Liabilities was $11.92 Mil.
Net Income was -5.101 + -10.338 + -9.736 + -8.102 = $-33.28 Mil.

Revenue was 10.988 + 3.698 + 5.37 + 5.846 = $25.90 Mil.
Gross Profit was 10.988 + 3.698 + 5.37 + 5.846 = $25.90 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(153.56 + 137.115 + 114.309 + 99.163 + 95.49) / 5 = $119.9274 Mil.
Total Assets at the begining of last year (Dec21) was $153.56 Mil.
Long-Term Debt & Capital Lease Obligation was $12.24 Mil.
Total Current Assets was $73.42 Mil.
Total Current Liabilities was $36.58 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pieris Pharmaceuticals's current Net Income (TTM) was -24.54. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pieris Pharmaceuticals's current Cash Flow from Operations (TTM) was -53.82. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-24.543/95.49
=-0.25702168

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-33.277/153.56
=-0.21670357

Pieris Pharmaceuticals's return on assets of this year was -0.25702168. Pieris Pharmaceuticals's return on assets of last year was -0.21670357. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Pieris Pharmaceuticals's current Net Income (TTM) was -24.54. Pieris Pharmaceuticals's current Cash Flow from Operations (TTM) was -53.82. ==> -53.82 <= -24.54 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0/72.6696
=0

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=12.244/119.9274
=0.1020951

Pieris Pharmaceuticals's gearing of this year was 0. Pieris Pharmaceuticals's gearing of last year was 0.1020951. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=38.68/11.922
=3.24442208

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=73.424/36.583
=2.00705246

Pieris Pharmaceuticals's current ratio of this year was 3.24442208. Pieris Pharmaceuticals's current ratio of last year was 2.00705246. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Pieris Pharmaceuticals's number of shares in issue this year was 1.237. Pieris Pharmaceuticals's number of shares in issue last year was 0.931. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=42.81/42.81
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=25.902/25.902
=1

Pieris Pharmaceuticals's gross margin of this year was 1. Pieris Pharmaceuticals's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=42.81/95.49
=0.4483192

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=25.902/153.56
=0.16867674

Pieris Pharmaceuticals's asset turnover of this year was 0.4483192. Pieris Pharmaceuticals's asset turnover of last year was 0.16867674. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+1+1+0+0+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pieris Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Pieris Pharmaceuticals  (NAS:PIRS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Pieris Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Pieris Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Pieris Pharmaceuticals (Pieris Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
225 Franklin Street, 26th Floor, Boston, MA, USA, 02110
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States.
Executives
Ann Barbier director 255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109
Peter A Kiener director 40 GUEST STREET, BOSTON MA 02135
Maya R. Said director C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Matthew L Sherman director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Christopher P Kiritsy director
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Shane Olwill officer: Chief Development Officer C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Ahmed Mousa officer: Chief Business Officer 255 STATE STREET, 9TH FLOOR, C/O PIERIS PHARMACEUTICALS, INC., BOSTON MA 02109
Hitto Kaufmann officer: Chief Scientific Officer C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Thomas Bures officer: Chief Financial Officer C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Tim Demuth officer: Chief Medical Officer C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109
Aquilo Capital Management, Llc 10 percent owner ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO CA 94129
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104